UA83648C2 - Антагонисты аденозиндифосфатного рецептора тромбоцитов - Google Patents

Антагонисты аденозиндифосфатного рецептора тромбоцитов

Info

Publication number
UA83648C2
UA83648C2 UAA200506729A UA2005006729A UA83648C2 UA 83648 C2 UA83648 C2 UA 83648C2 UA A200506729 A UAA200506729 A UA A200506729A UA 2005006729 A UA2005006729 A UA 2005006729A UA 83648 C2 UA83648 C2 UA 83648C2
Authority
UA
Ukraine
Prior art keywords
adenosine diphosphate
receptor antagonists
compounds
platelet adenosine
diphosphate receptor
Prior art date
Application number
UAA200506729A
Other languages
English (en)
Ukrainian (uk)
Inventor
Джуди Брайант
Бред Бакман
Имадул Ислам
Раджу Мохан
Майкл Морриссей
Гуо Пинг Вей
Вей Ксю
Шендонг Юан
Original Assignee
Шеринг Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шеринг Акциенгезельшафт filed Critical Шеринг Акциенгезельшафт
Publication of UA83648C2 publication Critical patent/UA83648C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

В заявке описаны соединения следующей формулы:,в которой m, n, R, R, R, Rи Rописаны в данном изобретении, применимы как ингибиторы аденозиндифосфата тромбоцитов. В заявке также описаны фармацевтические композиции, которые содержат эти соединения, способы применения этих соединений в качестве антитромботических средств и способы синтеза этих соединений.
UAA200506729A 2002-12-11 2003-12-09 Антагонисты аденозиндифосфатного рецептора тромбоцитов UA83648C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43279202P 2002-12-11 2002-12-11
PCT/US2003/039079 WO2004052366A1 (en) 2002-12-11 2003-12-09 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists

Publications (1)

Publication Number Publication Date
UA83648C2 true UA83648C2 (ru) 2008-08-11

Family

ID=32507994

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200506729A UA83648C2 (ru) 2002-12-11 2003-12-09 Антагонисты аденозиндифосфатного рецептора тромбоцитов

Country Status (23)

Country Link
US (2) US7056923B2 (ru)
EP (1) EP1578423B1 (ru)
JP (1) JP4662777B2 (ru)
KR (1) KR20050085580A (ru)
CN (1) CN1747732A (ru)
AP (1) AP2005003363A0 (ru)
AT (1) ATE477800T1 (ru)
AU (1) AU2003297763A1 (ru)
BR (1) BR0317222A (ru)
CA (1) CA2507657C (ru)
DE (1) DE60333866D1 (ru)
EA (1) EA200500899A1 (ru)
EC (1) ECSP055912A (ru)
ES (1) ES2348942T3 (ru)
MX (1) MXPA05006302A (ru)
NO (1) NO20053335L (ru)
NZ (1) NZ540872A (ru)
OA (1) OA12970A (ru)
PL (1) PL377053A1 (ru)
RS (1) RS20050450A (ru)
UA (1) UA83648C2 (ru)
WO (1) WO2004052366A1 (ru)
ZA (1) ZA200505492B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
WO2005040174A1 (en) * 2003-10-21 2005-05-06 Inspire Pharmaceuticals, Inc. Tetrahydro-furo`3,4-d!dioxole compounds and compositions and method for inhibiting platelet aggregation
TW200640877A (en) * 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
CA2619706A1 (en) * 2005-08-17 2007-02-22 Schering Corporation Novel high affinity quinoline-based kinase ligands
DE102006020385A1 (de) * 2006-04-28 2007-10-31 Dade Behring Marburg Gmbh Verfahren und Vorrichtung zur Bestimmung der Thrombozytenfunktion unter Flussbedingungen
CL2007002920A1 (es) * 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
BRPI0810462A2 (pt) * 2007-04-23 2014-10-14 Sanofi Aventis Derivados de quinolina-carboxamida como antagonistas de p2y12
BRPI0812912A2 (pt) 2007-06-18 2014-12-09 Sanofi Aventis Derivados de pirrol como antagonistas de p2y12
US8518912B2 (en) 2007-11-29 2013-08-27 Actelion Pharmaceuticals Ltd. Phosphonic acid derivates and their use as P2Y12 receptor antagonists
AR071652A1 (es) * 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
BRPI1014039A2 (pt) * 2009-04-08 2018-04-03 Actelion Pharmaceuticals Ltd 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas
US8664203B2 (en) 2009-04-22 2014-03-04 Actelion Pharmaceuticals Ltd. Thiazole derivatives and their use as P2Y12 receptor antagonists
CN102304108B (zh) * 2011-06-28 2013-11-06 中国药科大学 五元杂环双羰基衍生物及其抗多药耐药细菌上的用途
CN104151235B (zh) * 2014-08-07 2016-01-20 南阳师范学院 一种喹啉衍生物制备方法
KR102552795B1 (ko) 2016-09-22 2023-07-06 이도르시아 파마슈티컬스 리미티드 결정질 형태
JP2020510043A (ja) 2017-03-15 2020-04-02 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｙ１２受容体アンタゴニストの皮下投与
CN112062687B (zh) * 2020-09-02 2023-11-21 上海信谊万象药业股份有限公司 一种盐酸阿扎司琼中间体3-氨基-5-氯-2-羟基苯甲酸甲酯的合成方法
CN112920181A (zh) * 2021-01-29 2021-06-08 中国医科大学 N-(5-苯基-1,3,4-噻二唑-2-基)苯甲酰胺类化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US60474A (en) * 1866-12-18 Pbtee chick
GB1334705A (en) 1970-06-19 1973-10-24 Ici Ltd Pharmaceutical compositions containing kynurenic acid derivatives
US4258192A (en) * 1977-12-16 1981-03-24 Mitsubishi Chemical Industries Limited N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US5346907A (en) * 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
EP0511347A1 (de) 1990-11-15 1992-11-04 Pentapharm A.G. Meta-substituierte phenylalanin-derivate
HUT68042A (en) * 1993-02-10 1995-03-22 Pentapharm Ag Piperazides of substituted phenylalanine derivates as thrombin inhibitors
KR0173034B1 (ko) * 1995-04-28 1999-03-30 성재갑 선택적 트롬빈 억제제
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists

Also Published As

Publication number Publication date
EP1578423A1 (en) 2005-09-28
EA200500899A1 (ru) 2006-02-24
PL377053A1 (pl) 2006-01-23
WO2004052366A9 (en) 2005-06-23
JP4662777B2 (ja) 2011-03-30
MXPA05006302A (es) 2005-08-29
US20060122188A1 (en) 2006-06-08
US20040138229A1 (en) 2004-07-15
KR20050085580A (ko) 2005-08-29
ECSP055912A (es) 2005-11-22
CA2507657C (en) 2011-05-31
JP2006511519A (ja) 2006-04-06
NO20053335D0 (no) 2005-07-08
DE60333866D1 (de) 2010-09-30
NO20053335L (no) 2005-09-07
ES2348942T3 (es) 2010-12-17
EP1578423B1 (en) 2010-08-18
CA2507657A1 (en) 2004-06-24
CN1747732A (zh) 2006-03-15
US7056923B2 (en) 2006-06-06
AU2003297763A1 (en) 2004-06-30
NZ540872A (en) 2007-08-31
RS20050450A (en) 2007-08-03
ZA200505492B (en) 2006-03-29
AP2005003363A0 (en) 2005-09-30
US7084142B2 (en) 2006-08-01
ATE477800T1 (de) 2010-09-15
OA12970A (en) 2006-10-13
BR0317222A (pt) 2005-11-01
WO2004052366A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
UA83648C2 (ru) Антагонисты аденозиндифосфатного рецептора тромбоцитов
MXPA03010207A (es) Nuevas 4-anilinoquinolin-3-carboxamidas.
WO2002098856A3 (en) Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists
DE602004021472D1 (en) Pyrimiidinverbindungen
AU2003228770A8 (en) Substituted pyrazolopyrimidines
SE0200920D0 (sv) Novel compounds
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
NO20050525L (no) Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
ID27535A (id) Turunan pirasola sebagai inhibitor p-38 map kinase
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
MXPA05011296A (es) Conjugados de fosfonato inhibidores de la cinasa.
DE60212949D1 (de) Antivirale pyrazolopyridin verbindungen
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
TW200604197A (en) New compounds
DE60201074D1 (en) Pyrazolopyridinderivate
BR0308601A (pt) inibidores de carboxipeptidase b de plasma
SE9904128D0 (sv) Novel compounds
DE60100539D1 (en) Tosylprolin-derivate als thymidylat-synthase inhibitoren
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
MXPA05006530A (es) Derivados de 1-n-fenilamino-1h-imidazola como inhibidores aromatasa.
TNSN05161A1 (en) 1-n-phenylamino-1h-imidazole derivatives as aromatase inhibitors